Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Paladin Labs gets rights to Immuron's Travelan and option to IMM255

Executive Summary

Australian biotech Immuron Ltd. (developing dairy-derived antibody therapeutics) has licensed Canadian specialty pharmaco Paladin Labs Inc. exclusive rights to market and sell the over-the-counter traveler’s diarrhea drug Travelan in Canada, Latin America, Argentina, Brazil, Columbia, Mexico, sub-Saharan Africa, and South Africa. Paladin also has the option to acquire rights to Immuron's preclinical influenza candidate IMM255 in the same territories.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register